Alexander M. Busch, Ph.D.
Affiliations: | 2013 | Pharmacology and Toxicology | Dartmouth College, Hanover, NH, United States |
Area:
Pharmacology, OncologyGoogle:
"Alexander Busch"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Ethan Dmitrovsky | grad student | 2013 | Dartmouth | |
| (Pharmacological targeting of wnt and hedgehog pathways in lung cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Busch AM, Galimberti F, Nehls KE, et al. (2014) All-trans-retinoic acid antagonizes the Hedgehog pathway by inducing patched. Cancer Biology & Therapy. 15: 463-72 |
| Busch AM, Johnson KC, Stan RV, et al. (2013) Evidence for tankyrases as antineoplastic targets in lung cancer. Bmc Cancer. 13: 211 |
| Galimberti F, Busch AM, Chinyengetere F, et al. (2012) Response to inhibition of smoothened in diverse epithelial cancer cells that lack smoothened or patched 1 mutations. International Journal of Oncology. 41: 1751-61 |
| Busch AM, Johnson KC, Tacchelly O, et al. (2012) Abstract 973: Tankyrase inhibition represses Wnt signaling and lung cancer growth Cancer Research. 72: 973-973 |
| Dragnev KH, Ma T, Cyrus J, et al. (2011) Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prevention Research (Philadelphia, Pa.). 4: 818-28 |
| Dragnev KH, Ma T, Cyrus J, et al. (2011) Abstract LB-412: Combining bexarotene with erlotinib in window of opportunity and phase II trials causes lung cancer responses independent of KRAS mutations Cancer Research. 71 |
| Guo Y, Dolinko A, Chinyengetere F, et al. (2010) Abstract 1594: Targeting UBP43 for repression destabilizes PML/RARα and inhibits acute promyelocytic leukemia growth Cancer Research. 70: 1594-1594 |
| Snow GE, Kasper AC, Busch AM, et al. (2009) Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting. Bmc Cancer. 9: 383 |